Cargando…

Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats

The increased deposition of iron in the kidneys that occurs with glomerulopathy hinders the functional and structural recovery of the tubules and promotes progression of chronic kidney disease (CKD). Here, we evaluated whether epoetin beta pegol (continuous erythropoietin receptor activator: CERA),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirata, Michinori, Tashiro, Yoshihito, Aizawa, Ken, Kawasaki, Ryohei, Shimonaka, Yasushi, Endo, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760454/ https://www.ncbi.nlm.nih.gov/pubmed/26634903 http://dx.doi.org/10.14814/phy2.12637

Ejemplares similares

Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease
por: Aizawa, Ken, et al.
Publicado: (2018)

Epoetin beta pegol ameliorates flow‐mediated dilation with improving endothelial nitric oxide synthase coupling state in nonobese diabetic rats
por: Serizawa, Kenichi, et al.
Publicado: (2017)

Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study)
por: Hayashi, Terumasa, et al.
Publicado: (2018)

Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis
por: Iwasaki, Takahide, et al.
Publicado: (2021)

Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2017)

A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation
por: Oka, Satoru, et al.
Publicado: (2017)

MPO-ANCA Rapidly Progressive Glomerulonephritis with Immune Deposits
por: Acosta, Eric, et al.
Publicado: (2022)

The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2023)

Management of Rapidly Progressive Glomerulonephritis
por: Gaskin, Gill
Publicado: (1997)

Rapidly progressive glomerulonephritis in children
por: Moorani, Khemchand N, et al.
Publicado: (2022)

Sjögren Syndrome-Related Membranous Glomerulonephritis Progressing to Membranoproliferative Glomerulonephritis
por: Yabuuchi, Junko, et al.
Publicado: (2016)

Fibrillary Glomerulonephritis: A Great Mimicker of Rapidly Progressive Glomerulonephritis
por: Raikar, Manisha, et al.
Publicado: (2022)

Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient
por: Shingu, Yasuki, et al.
Publicado: (2020)

Visualization of (57)Fe-Labeled Heme Isotopic Fine Structure and Localization of Regions of Erythroblast Maturation in Mouse Spleen by MALDI FTICR-MS Imaging
por: Kihara, Makoto, et al.
Publicado: (2017)

Progression of Medial Arterial Calcification in CKD
por: Manzoor, Shumila, et al.
Publicado: (2018)

A predictive model for progression of CKD
por: Chang, Hsueh-Lu, et al.
Publicado: (2019)

Optimizing Diet to Slow CKD Progression
por: Molina, Pablo, et al.
Publicado: (2021)

Fibrillary glomerulonephritis: presenting as crescentic glomerulonephritis causing rapidly progressive renal failure
por: Nilajgi, Shalini, et al.
Publicado: (2011)

What is new in the management of rapidly progressive glomerulonephritis?
por: Greenhall, George H.B., et al.
Publicado: (2015)

Use of Rituximab in Management of Rapidly Progressive Glomerulonephritis
por: Cancarevic, Ivan, et al.
Publicado: (2020)

Atypical presentation of syphilis: Rapidly progressive glomerulonephritis
por: Usmael, Semir Abdi, et al.
Publicado: (2023)

CKD Progression and Economic Burden in Individuals With CKD Associated With Type 2 Diabetes
por: Mullins, C. Daniel, et al.
Publicado: (2022)

Quality of Original and Biosimilar Epoetin Products
por: Brinks, Vera, et al.
Publicado: (2010)

Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin β pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2021)

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
por: Fishbane, Steven, et al.
Publicado: (2019)

Chapter 3: Management of progression and complications of CKD
Publicado: (2013)

Self-reported Medication Adherence and CKD Progression
por: Cedillo-Couvert, Esteban A., et al.
Publicado: (2018)

APOL1, Acid Load, and CKD Progression
por: Pike, Mindy, et al.
Publicado: (2019)

Risk Factors and Rate of Progression of CKD in Children
por: Kamath, Nivedita, et al.
Publicado: (2019)

Eubicarbonatemic Hydrogen Ion Retention and CKD Progression
por: Madias, Nicolaos E.
Publicado: (2021)

Risk Factors for Progression of CKD with and without Diabetes
por: Zhang, Xiaohong, et al.
Publicado: (2022)

Urinary Metabolite Profile Predicting the Progression of CKD
por: Kim, Yaerim, et al.
Publicado: (2023)

Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis
por: Aapro, M, et al.
Publicado: (2006)

Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury
por: Irrera, Natasha, et al.
Publicado: (2015)

Oxygenation Inhibits the Physiological Tissue-Protecting Mechanism and Thereby Exacerbates Acute Inflammatory Lung Injury
por: Thiel, Manfred, et al.
Publicado: (2005)

Predictors of outcome in idiopathic rapidly progressive glomerulonephritis (IRPGN)
por: Alexopoulos, Efstathios, et al.
Publicado: (2006)

Avacopan in Patients With Rapidly Progressive Glomerulonephritis Requiring Dialysis
por: Cortazar, Frank B., et al.
Publicado: (2023)

Effectiveness of CKD Exacerbation Countermeasures in Izumo City
por: Ito, Takafumi, et al.
Publicado: (2021)

The Use of Epoetin-α in Revision Knee Arthroplasty
por: Delasotta, Lawrence A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_foq4s8kguqi6f7r3ee657ih9cd